Relationship between Toxoplasma Gondii and Psychotic Disorders with Implications toward a Brain-based Diagnostic System and Novel Treatment Approaches: A Study Protocol
Journal of Advances in Medicine and Medical Research,
Page 82-88
DOI:
10.9734/jammr/2021/v33i1330958
Abstract
What role infectious agents play in the causation of psychotic disorders? To investigate this area, we have aimed to investigate the relationship between Toxoplasma gondii and psychotic disorders. A hospital-based cross-sectional study is designed. IgM and IgG antibodies to T. gondii in patients with psychotic disorders will be measured and presented in result. Seropositivity rates will be compared with first-degree relatives and healthy volunteers. Also, types of psychotic disorders and seropositivity rate will be compared. Here, we are presenting the study protocol with implications toward a brain-based diagnostic system and novel treatment approaches.
Keywords:
- Toxoplasma gondii
- psychotic disorders
- diagnostic system
- seropositivity rate
How to Cite
References
Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003;62(3):237-44. DOI: 10.1016/s0920-9964(02)00357-2. PMID: 12837520.
Abdollahian E, Shafiei R, Mokhber N, Kalantar K, Fata A. Seroepidemiological study of Toxoplasma gondii infection among psychiatric patients in Mashhad, Northeast of Iran. Iran J Parasitol. 2017;12(1):117-22. PMID: 28761468; PMCID: PMC5522687.
Chen X, Chen B, Hou X, Zheng C, Yang X, Ke J, et al. Association between Toxoplasma gondii infection and psychiatric disorders in Zhejiang, Southeastern China. Acta Trop. 2019;192:82-6. DOI: 10.1016/j.actatropica. 2019.02.001. Epub 2019 Feb 4. PMID: 30731066.
Yolken R, Torrey EF, Dickerson F. Evidence of increased exposure to Toxoplasma gondii in individuals with recent onset psychosis but not with established schizophrenia. PLoS Negl Trop Dis. 2017;11(11):e0006040. DOI: 10.1371/journal.pntd.0006040. PMID: 29108011; PMCID: PMC5690692.
World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
Abd El-Aal NF, Saber M, Fawzy N, Ashour WR. Sero-prevalence of anti-Toxoplasma gondii antibodies among patients with neuropsychiatric disorders: epilepsy and depression. J Egypt Soc Parasitol. 2016;46(3):729-36. PMID: 30230768.
Yalın Sapmaz Ş, Şen S, Özkan Y, Kandemir H. Relationship between Toxoplasma gondii seropositivity and depression in children and adolescents. Psychiatry Res. 2019;278:263-7. DOI:10.1016/j.psychres.2019.06.031. Epub 2019 Jun 20. PMID: 31238296.
Sari SA, Kara A. Association of suicide attempt with seroprevalence of Toxoplasma gondii in adolescents. J Nerv Ment Dis. 2019;207(12):1025-30. DOI:10.1097/NMD.0000000000001046. PMID: 31688493.
Equator Network. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials; 2021. Accessed 29 March 2021. Available: https://www.equator-network.or g/reporting-guidelines/spirit-2013-statement-defining-stand
-
Abstract View: 619 times
PDF Download: 264 times
